Analyst Price Targets — AMPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 3, 2026 9:36 am | — | Barclays | $20.00 | $18.45 | TheFly | Amphastar price target lowered to $20 from $23 at Barclays |
| May 14, 2026 9:15 am | Benjamin Burnett | Wells Fargo | $19.00 | $18.32 | TheFly | Amphastar downgraded to Equal Weight from Overweight at Wells Fargo |
| May 11, 2026 11:00 am | — | Piper Sandler | $21.00 | $19.00 | TheFly | Amphastar price target lowered to $21 from $25 at Piper Sandler |
| April 20, 2026 8:27 pm | Dennis Ding | Jefferies | $22.00 | $22.92 | TheFly | Amphastar downgraded to Hold from Buy at Jefferies |
| December 8, 2025 9:25 pm | — | Barclays | $30.00 | $26.01 | TheFly | Amphastar initiated with an Equal Weight at Barclays |
| March 21, 2025 10:48 am | David Amsellem | Piper Sandler | $32.00 | $28.29 | TheFly | Amphastar price target lowered to $32 from $36 at Piper Sandler |
| August 8, 2024 8:06 am | David Amsellem | Piper Sandler | $66.00 | $43.31 | StreetInsider | Amphastar Pharmaceuticals (AMPH) PT Lowered to $66 at Piper Sandler |
| May 23, 2024 8:45 am | David Amsellem | Piper Sandler | $71.00 | $43.31 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Amphastar Pharmaceuticals (AMPH) |
| March 12, 2022 12:00 am | David Amsellem | Piper Sandler | $35.00 | $34.30 | Pulse 2.0 | Amphastar Pharmaceuticals (AMPH) Stock: Why The Price Jumped Up |
Latest News for AMPH
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
Amphastar Pharmaceuticals NASDAQ: AMPH is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors at the East Coast IDEAS Conference.
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMPH.
U.S. House Trading
No House trades found for AMPH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.